ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response

Study Summary

The goal of this clinical trial is to learn if ACP-211 can help treat adults with major depressive disorder (MDD) who have not improved with antidepressant therapy (ADT), including those with treatment resistant depression (TRD). The main questions the study aims to answer are: * Does ACP-211 work better than a placebo (a look-alike capsule with no medicine) to reduce symptoms of depression? * What adverse events do participants have when taking ACP-211?

Conditions

Major Depressive Disorder (MDD)Depressive Disorder, Treatment-Resistant

Interventions / Drugs

ACP-211 Placebo

View on ClinicalTrials.gov ↗

Sponsor

ACAD

ACADIA Pharmaceuticals

Neuroscience

D50/100

Study Details

Enrollment153 participants

Primary Completion—

Lead SponsorACADIA Pharmaceuticals Inc.

Data Retrieved2026-04-11 02:52:05.276977+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.